Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten in symptomatic obstructive hypertrophic cardiomyopathy
2017-002530-23Phase 3Completed
- Sponsor
- MyoKardia
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypertrophic cardiomyopathy (HCM) comparing Mavacamten with Placebo (2 arms). Primary endpoint: Clinical response. Started May 2018; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on 2017-002530-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002530-23.